

Jim C Oates

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4993596/publications.pdf>

Version: 2024-02-01

82
papers

2,482
citations

159585

30
h-index

214800

47
g-index

83
all docs

83
docs citations

83
times ranked

3096
citing authors

#	ARTICLE	IF	CITATIONS
1	Urine Biomarkers Predict the Cause of Glomerular Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2007, 18, 913-922.	6.1	205
2	At the Bedside: Neutrophil extracellular traps (NETs) as targets for biomarkers and therapies in autoimmune diseases. <i>Journal of Leukocyte Biology</i> , 2016, 99, 265-278.	3.3	144
3	Thrombosis in patients with connective tissue diseases treated with specific cyclooxygenase 2 inhibitors: A report of four cases. <i>Arthritis and Rheumatism</i> , 2000, 43, 1891-1896.	6.7	142
4	Upregulation of xCT by KSHV-Encoded microRNAs Facilitates KSHV Dissemination and Persistence in an Environment of Oxidative Stress. <i>PLoS Pathogens</i> , 2010, 6, e1000742.	4.7	98
5	Curcumin-Induced Apoptosis in Scleroderma Lung Fibroblasts. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2004, 31, 28-35.	2.9	86
6	Prospective Measure of Serum 3-Nitrotyrosine Levels in Systemic Lupus Erythematosus: Correlation with Disease Activity. <i>Proceedings of the Association of American Physicians</i> , 1999, 111, 611-621.	2.0	77
7	The biology of nitric oxide and other reactive intermediates in systemic lupus erythematosus. <i>Clinical Immunology</i> , 2006, 121, 243-250.	3.2	74
8	A Link Between Plasma Microbial Translocation, Microbiome, and Autoantibody Development in First-Degree Relatives of Systemic Lupus Erythematosus Patients. <i>Arthritis and Rheumatology</i> , 2019, 71, 1858-1868.	5.6	71
9	Inhibition of Mesangial Cell Nitric Oxide in MRL/lpr Mice by Prostaglandin J2 and Proliferator Activation Receptor- β Agonists. <i>Journal of Immunology</i> , 2000, 164, 1498-1504.	0.8	70
10	Prediction of urinary protein markers in lupus nephritis. <i>Kidney International</i> , 2005, 68, 2588-2592.	5.2	65
11	Renal Glycosphingolipid Metabolism Is Dysfunctional in Lupus Nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 1402-1413.	6.1	63
12	Rheumatology Informatics System for Effectiveness: A National Informatics-Enabled Registry for Quality Improvement. <i>Arthritis Care and Research</i> , 2016, 68, 1866-1873.	3.4	61
13	Effect of Late Modulation of Nitric Oxide Production on Murine Lupus. <i>Clinical Immunology and Immunopathology</i> , 1997, 83, 86-92.	2.0	60
14	Premature Atherosclerosis Is Associated With Hypovitaminosis D and Angiotensin-Converting Enzyme Inhibitor Non-use in Lupus Patients. <i>American Journal of the Medical Sciences</i> , 2012, 344, 268-273.	1.1	60
15	Caveolin-1 regulates leucocyte behaviour in fibrotic lung disease. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1220-1226.	0.9	58
16	Distinct PKC isoforms mediate cell survival and DNA synthesis in thrombin-induced myofibroblasts. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2005, 288, L190-L201.	2.9	57
17	IFN- γ Negatively Regulates the Expression of Endothelial Nitric Oxide Synthase and Nitric Oxide Production: Implications for Systemic Lupus Erythematosus. <i>Journal of Immunology</i> , 2017, 199, 1979-1988.	0.8	57
18	Prostaglandin J2 Inhibition of Mesangial Cell iNOS Expression. <i>Clinical Immunology</i> , 2001, 98, 337-345.	3.2	54

#	ARTICLE	IF	CITATIONS
19	Association of serum nitrate and nitrite levels with longitudinal assessments of disease activity and damage in systemic lupus erythematosus and lupus nephritis. <i>Arthritis and Rheumatism</i> , 2008, 58, 263-272.	6.7	51
20	Progesterone decreases gut permeability through upregulating occludin expression in primary human gut tissues and Caco-2 cells. <i>Scientific Reports</i> , 2019, 9, 8367.	3.3	49
21	Mediators of injury in lupus nephritis. <i>Current Opinion in Rheumatology</i> , 2002, 14, 498-503.	4.3	44
22	Development of Biomarker Models to Predict Outcomes in Lupus Nephritis. <i>Arthritis and Rheumatology</i> , 2016, 68, 1955-1963.	5.6	42
23	The biology of reactive intermediates in systemic lupus erythematosus. <i>Autoimmunity</i> , 2010, 43, 56-63.	2.6	41
24	Rituximab-responsive Cryoglobulinemic Glomerulonephritis in a Patient With Autoimmune Hepatitis. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 862-863.	2.2	37
25	Nitric oxide synthase 2 promoter polymorphisms and systemic lupus erythematosus in african-americans. <i>Journal of Rheumatology</i> , 2003, 30, 60-7.	2.0	36
26	Overcoming the Effects of Matrix Interference in the Measurement of Urine Protein Analytes. <i>Biomarker Insights</i> , 2012, 7, BMI.S8703.	2.5	34
27	Inhibition of Sphingosine Kinase-2 in a Murine Model of Lupus Nephritis. <i>PLoS ONE</i> , 2013, 8, e53521.	2.5	34
28	A Critical Role of the Transcription Factor $\text{NF-}\kappa\text{B}$ in Murine Lupus Development by Regulation of Interleukin-6 Expression. <i>Arthritis and Rheumatology</i> , 2014, 66, 3436-3444.	5.6	34
29	Endothelial Nitric Oxide Synthase Reduces Crescentic and Necrotic Glomerular Lesions, Reactive Oxygen Production, and MCP1 Production in Murine Lupus Nephritis. <i>PLoS ONE</i> , 2013, 8, e64650.	2.5	33
30	Peroxisome proliferator-activated receptor γ agonists: Potential use for treating chronic inflammatory diseases. <i>Arthritis and Rheumatism</i> , 2002, 46, 598-605.	6.7	30
31	Peer-to-Peer Mentoring for African American Women With Lupus: A Feasibility Pilot. <i>Arthritis Care and Research</i> , 2018, 70, 908-917.	3.4	26
32	Inducible Nitric Oxide Synthase Inhibitors Reduce Urinary Markers of Systemic Oxidant Stress in Murine Proliferative Lupus Nephritis. <i>Journal of Investigative Medicine</i> , 2005, 53, 347-352.	1.6	25
33	A Pilot Study to Determine if Vitamin D Repletion Improves Endothelial Function in Lupus Patients. <i>American Journal of the Medical Sciences</i> , 2015, 350, 302-307.	1.1	25
34	Effective Self-Management Interventions for Patients With Lupus: Potential Impact of Peer Mentoring. <i>American Journal of the Medical Sciences</i> , 2017, 353, 580-592.	1.1	22
35	Lack of nitric oxide synthases increases lipoprotein immune complex deposition in the aorta and elevates plasma sphingolipid levels in lupus. <i>Cellular Immunology</i> , 2012, 276, 42-51.	3.0	20
36	Antiphospholipid Antibodies and Heart Valve Disease in Systemic Lupus Erythematosus. <i>American Journal of the Medical Sciences</i> , 2018, 355, 293-298.	1.1	20

#	ARTICLE	IF	CITATIONS
37	Role of Interferon Alpha in Endothelial Dysfunction: Insights Into Endothelial Nitric Oxide Synthase-Related Mechanisms. <i>American Journal of the Medical Sciences</i> , 2014, 348, 168-175.	1.1	19
38	A population-based approach for implementing change from opt-out to opt-in research permissions. <i>PLoS ONE</i> , 2017, 12, e0168223.	2.5	19
39	SLE-key [®] rule-out serologic test for excluding the diagnosis of systemic lupus erythematosus: Developing the ImmunArray iCHIP [®] . <i>Journal of Immunological Methods</i> , 2016, 429, 1-6.	1.4	18
40	Research participation preferences as expressed through a patient portal: implications of demographic characteristics. <i>JAMIA Open</i> , 2018, 1, 202-209.	2.0	18
41	Prediction models of treatment response in lupus nephritis. <i>Kidney International</i> , 2022, 101, 379-389.	5.2	18
42	Camptothecin and Topotecan, Inhibitors of Transcription Factor Flt-1 and Topoisomerase, Markedly Ameliorate Lupus Nephritis in (NZB × NZW)F1 Mice and Reduce the Production of Inflammatory Mediators in Human Renal Cells. <i>Arthritis and Rheumatology</i> , 2021, 73, 1478-1488.	5.6	17
43	Nitric Oxide Induces Apoptosis in Spleen Lymphocytes from MRL/lpr Mice. <i>Journal of Investigative Medicine</i> , 2004, 52, 62-71.	1.6	16
44	Inducible Nitric Oxide Synthase Inhibitor SD-3651 Reduces Proteinuria in MRL/lpr Mice Deficient in the NOS2 Gene. <i>Journal of Investigative Medicine</i> , 2008, 56, 911-919.	1.6	15
45	Variable Association of Reactive Intermediate Genes with Systemic Lupus Erythematosus in Populations with Different African Ancestry. <i>Journal of Rheumatology</i> , 2013, 40, 842-849.	2.0	15
46	Association of reactive oxygen and nitrogen intermediate and complement levels with apoptosis of peripheral blood mononuclear cells in lupus patients. <i>Arthritis and Rheumatism</i> , 2007, 56, 3738-3747.	6.7	14
47	NADPH oxidase and nitric oxide synthase-dependent superoxide production is increased in proliferative lupus nephritis. <i>Lupus</i> , 2013, 22, 1361-1370.	1.6	13
48	Improving clinical trial accrual by streamlining the referral process. <i>International Journal of Medical Informatics</i> , 2015, 84, 15-23.	3.3	13
49	Peer approaches to self-management (PALS): comparing a peer mentoring approach for disease self-management in African American women with lupus with a social support control: study protocol for a randomized controlled trial. <i>Trials</i> , 2019, 20, 529.	1.6	13
50	Plasma Sphingolipid Profile Associated With Subclinical Atherosclerosis and Clinical Disease Markers of Systemic Lupus Erythematosus: Potential Predictive Value. <i>Frontiers in Immunology</i> , 2021, 12, 694318.	4.8	13
51	Development of a lupus nephritis suboptimal response prediction tool using renal histopathological and clinical laboratory variables at the time of diagnosis. <i>Lupus Science and Medicine</i> , 2021, 8, e000489.	2.7	13
52	Rigorous Plasma Microbiome Analysis Method Enables Disease Association Discovery in Clinic. <i>Frontiers in Microbiology</i> , 2020, 11, 613268.	3.5	12
53	Upregulated Interleukin-10 Induced by E2F Transcription Factor 2 MicroRNA Circuitry in Extrafollicular Effector B Cells Contributes to Autoantibody Production in Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2022, 74, 496-507.	5.6	12
54	The Place of William Osler in the Description of Systemic Lupus Erythematosus. <i>American Journal of the Medical Sciences</i> , 2009, 338, 409-412.	1.1	11

#	ARTICLE	IF	CITATIONS
55	Lipopolysaccharide induces inducible nitric oxide synthase-dependent podocyte dysfunction via a hypoxia-inducible factor 1 α and cell division control protein 42 and Ras-related C3 botulinum toxin substrate 1 pathway. <i>Free Radical Biology and Medicine</i> , 2015, 84, 185-195.	2.9	11
56	Cytokine balance and behavioral intervention; findings from the Peer Approaches to Lupus Self-Management (PALS) project. <i>Human Immunology</i> , 2017, 78, 574-581.	2.4	10
57	Developing and Validating Methods to Assemble Systemic Lupus Erythematosus Births in the Electronic Health Record. <i>Arthritis Care and Research</i> , 2022, 74, 849-857.	3.4	10
58	The SLE-key test serological signature: new insights into the course of lupus. <i>Rheumatology</i> , 2018, 57, 1632-1640.	1.9	9
59	Nitric Oxide Induces Apoptosis in Spleen Lymphocytes from MRL/lpr Mice. <i>Journal of Investigative Medicine</i> , 2004, 52, 062.	1.6	8
60	My life with lupus: contextual responses of African-American women with systemic lupus participating in a peer mentoring intervention to improve disease self-management. <i>BMJ Open</i> , 2018, 8, e022701.	1.9	7
61	Lupus serum induces inflammatory interaction with neutrophils in human glomerular endothelial cells. <i>Lupus Science and Medicine</i> , 2020, 7, e000418.	2.7	7
62	“We Would Still Find Things to Talk About” Assessment of Mentor Perspectives in a Systemic Lupus Erythematosus Intervention to Improve Disease Self-Management, Empowering SLE Patients. <i>Journal of the National Medical Association</i> , 2018, 110, 182-189.	0.8	6
63	L-sepiapterin restores SLE serum-induced markers of endothelial function in endothelial cells. <i>Lupus Science and Medicine</i> , 2019, 6, e000294.	2.7	6
64	Association Between the Anti-Aging Gene Klotho and Selected Rheumatologic Autoimmune Diseases. <i>American Journal of the Medical Sciences</i> , 2021, 361, 169-175.	1.1	6
65	The Care-coordination Approach to Learning Lupus Self-Management: a patient navigator intervention for systemic lupus inpatients. <i>Lupus Science and Medicine</i> , 2021, 8, e000482.	2.7	6
66	Endothelial Dysfunction in Injury and Inflammation. <i>American Journal of the Medical Sciences</i> , 2015, 349, 2.	1.1	4
67	The Role of Reactive Nitrogen and Oxygen Intermediates in Systemic Lupus Erythematosus. , 2011, , 199-211.		3
68	Support Methodologies for African American Women With Lupus “Comparing Three Methods” Effects on Patient Activation and Coping. <i>Frontiers in Psychology</i> , 2021, 12, 734390.	2.1	3
69	Selective Cyclooxygenase-2 Inhibitor Suppresses Renal Thromboxane Production but Not Proliferative Lesions in the MRL/lpr Murine Model of Lupus Nephritis. <i>American Journal of the Medical Sciences</i> , 2011, 341, 101-105.	1.1	2
70	The association between method of solicitation and patient permissions for use of surplus tissues and contact for future research. <i>JAMIA Open</i> , 2018, 1, 195-201.	2.0	2
71	The Effect of Travel Burden on Depression and Anxiety in African American Women Living with Systemic Lupus. <i>Healthcare (Switzerland)</i> , 2021, 9, 1507.	2.0	2
72	ASSOCIATIONS BETWEEN ACCELERATED ATHEROSCLEROSIS, OXIDIZED LDL IMMUNE COMPLEXES, AND IN VITRO ENDOTHELIAL DYSFUNCTION IN SYSTEMIC LUPUS ERYTHEMATOSUS. <i>Transactions of the American Clinical and Climatological Association</i> , 2020, 131, 157-177.	0.5	2

#	ARTICLE	IF	CITATIONS
73	Nitric Oxide Induces Apoptosis in Spleen Lymphocytes from MRL/lpr Mice. Journal of Investigative Medicine, 2004, 52, 62-71.	1.6	1
74	Response to urinary protein markers in lupus nephritis: The need for concurrent calibration and discrimination statistics in predictive models. Kidney International, 2006, 70, 231-232.	5.2	1
75	The Magic of the Southern Society for Clinical Investigation: Can We Make the Vanishing Physician-Scientist Reappear?. American Journal of the Medical Sciences, 2013, 345, 259.	1.1	1
76	Presentation of the 2016 Foundersâ€™ Medal Award. American Journal of the Medical Sciences, 2016, 352, 6-8.	1.1	1
77	Reactive Nitrogen Intermediates in the Pathogenesis of Systemic Lupus Erythematosus. , 2016, , 243-253.		0
78	Tissue Damage in Lupus. , 2019, , 248-260.		0
79	2020 Southern Society for Clinical Investigation Foundersâ€™ Medal Award. American Journal of the Medical Sciences, 2020, 360, 83-84.	1.1	0
80	1103â€¦Perfluoroalkyl substances and community vulnerability: associations with lupus-related autoantibodies and disease. , 2021, , .		0
81	Variable selection methods for identifying predictor interactions in data with repeatedly measured binary outcomes. Journal of Clinical and Translational Science, 2021, 5, e59.	0.6	0
82	RASâ€¦mediated nitric oxide signaling in podocytes. FASEB Journal, 2022, 36, .	0.5	0